Cat. No.: HY-N0610A

Cinnamic acid

(Synonyms: 3-Phenylacrylic acid; β-Phenylacrylic acid)

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.98%
CAS No.: 621-82-9
Formule: C₉H₈O₂
Masse moléculaire:148.16

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Cinnamic acid Chemical Structure

CAS No.: 621-82-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	64 μM Compound: 16a	Anticancer activity against human A375 cells after 48 hrs by MTT assay Anticancer activity against human A375 cells after 48 hrs by MTT assay	[PMID: 22136907]
A549	IC₅₀	3.54 mM Compound: Cinnamic acid	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 31336310]
A549	IC₅₀	50.18 μM Compound: CA	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 24 hrs by MTT assay	10.1039/C6MD00178E
A549	IC₅₀	87 μM Compound: 16a	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22136907]
ACHN	IC₅₀	91 μM Compound: 16a	Anticancer activity against human ACHN cells after 48 hrs by MTT assay Anticancer activity against human ACHN cells after 48 hrs by MTT assay	[PMID: 22136907]
BALB/3T3	IC₅₀	671.4 μM Compound: 11	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BMDM	IC₅₀	>100 μM Compound: trans-cinnamic acid	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
BV-2	EC₅₀	>10 μM Compound: CA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay	[PMID: 29407994]
BV-2	IC₅₀	>100 μM Compound: 22	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
DLD-1	IC₅₀	0.685 μM Compound: 25, IWR-1	Inhibition of tankyrase in human DLD1 cells assessed as reduction in Wnt activity after 24 hrs by TCF-luciferase reporter gene assay Inhibition of tankyrase in human DLD1 cells assessed as reduction in Wnt activity after 24 hrs by TCF-luciferase reporter gene assay	[PMID: 25299683]
HeLa	IC₅₀	24.81 μM Compound: CA	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 24 hrs by MTT assay	10.1039/C6MD00178E
HT-144	IC₅₀	1.07 mM Compound: Cinnamic acid	Cytotoxicity against human HT144 cells after 48 hrs by MTT assay Cytotoxicity against human HT144 cells after 48 hrs by MTT assay	[PMID: 31336310]
HT-144	IC₅₀	2.4 mM Compound: Cinnamic acid	Cytotoxicity against human HT144 cells after 24 hrs by MTT assay Cytotoxicity against human HT144 cells after 24 hrs by MTT assay	[PMID: 31336310]
HT-22	EC₅₀	>10 μM Compound: CA	Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay	[PMID: 29407994]
HT-29	IC₅₀	114 μM Compound: 16a	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 22136907]
MCF7	IC₅₀	108 μM Compound: 16a	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22136907]
MIA PaCa-2	IC₅₀	1.33 mM Compound: Cinnamic acid	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 31336310]
NCI-H460	IC₅₀	2.1 mM Compound: Cinnamic acid	Cytotoxicity against human H460 cells after 48 hrs by MTT assay Cytotoxicity against human H460 cells after 48 hrs by MTT assay	[PMID: 31336310]
Oocyte	IC₅₀	34.6 μM Compound: Cin-COOH	Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique	[PMID: 23682762]
RAW264.7	GI₅₀	6547 μM Compound: 1d	Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay	10.1039/C3MD00251A

In Vitro

Treatment with Cinnamic acid (CINN) of various tumor cells of epithelial and neuroectodermal origin result in dose-dependent growth inhibition following a 3-day exposure. The inhibitory concentrations causing a 50% reduction in tumor-cell proliferation (IC₅₀) are between 1.2 to 4.5 mM. It is also showed that 20 mM Cinnamic acid is needed to cause an IC₅₀ in FS4 cells, i.e. 5 to 20 times more than for tumor cells. In addition to inhibiting tumor-cell proliferation, Cinnamic acid causes morphological changes consistent with melanocyte differentiation. Within 5 days of treatment with 5 mM Cinnamic acid, melanoma 1011 cells appear enlarged with a markedly increased cytoplasm-to-nuclear ratio and well organized cytoskeleton, developed long dendritic processes and became highly melanotic. The change in the capacity of Cinnamic acid -treated melanoma 1011, A375(M) and SKMEL28 cells to degrade and cross tissue barriers is assessed by an in vitro invasion assay using modified Boyden chambers with matrigel-coated filters. After 3 days of continuous treatment with Cinnamic acid, a dose-dependent loss of invasive capacity in 3 tested tumor lines is observed. Treatment with 5 mM Cinnamic acid results in 75-95% loss of invasiveness^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 621-82-9
Appearance Solid
Masse moléculaire 148.16
Formule C₉H₈O₂
Color White to off-white
SMILES

O=C(O)/C=C/C1=CC=CC=C1
Synonyms

3-Phenylacrylic acid; β-Phenylacrylic acid
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
Initial Source
- Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

J Neurosci

Pharmacological and Genetic Approaches to Downregulate FIS1 Mitigate Neuropathic Pain. [Abstract]

2025 Aug 27;45(35):e0523252025. PMID: 40769725
Res Sq

2025 Feb 05.
Res Sq

2025 Jan 31.

Solvant et solubilité

In Vitro:

Ethanol : ≥ 50 mg/mL (337.47 mM)

DMSO : 50 mg/mL (337.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.7495 mL

33.7473 mL

67.4946 mL

5 mM

1.3499 mL

6.7495 mL

13.4989 mL

10 mM

0.6749 mL

3.3747 mL

6.7495 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay

The cell lines used, established from human malignant tumors, are A549 (lung cancer); PC3(M), Du145, and LNCaP (prostate cancer); A172, U251 (glioblastoma); and SKMEL28, A375(M), 1011 (melanoma). Growth rates are determined by cell counting. Briefly, 5 X10⁴ cells are plated in each well of a 24-well plate, allowed to attach overnight, and treated with compounds (e.g., Cinnamic acid: 2.5, 5, 10, 20, 30 mM) the following day. Cells are grown for 3 days at 37°C in the presence or absence of the drug, then detached with trypsin/EDTA and counted in a Coulter counter. Viability is determined by Trypan-blue exclusion assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Liu L, et al. Cinnamic acid: a natural product with potential use in cancer intervention. Int J Cancer. 1995 Jul 28;62(3):345-50. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	6.7495 mL	33.7473 mL	67.4946 mL	168.7365 mL
	5 mM	1.3499 mL	6.7495 mL	13.4989 mL	33.7473 mL
	10 mM	0.6749 mL	3.3747 mL	6.7495 mL	16.8736 mL
	15 mM	0.4500 mL	2.2498 mL	4.4996 mL	11.2491 mL
	20 mM	0.3375 mL	1.6874 mL	3.3747 mL	8.4368 mL
	25 mM	0.2700 mL	1.3499 mL	2.6998 mL	6.7495 mL
	30 mM	0.2250 mL	1.1249 mL	2.2498 mL	5.6245 mL
	40 mM	0.1687 mL	0.8437 mL	1.6874 mL	4.2184 mL
	50 mM	0.1350 mL	0.6749 mL	1.3499 mL	3.3747 mL
	60 mM	0.1125 mL	0.5625 mL	1.1249 mL	2.8123 mL
	80 mM	0.0844 mL	0.4218 mL	0.8437 mL	2.1092 mL
	100 mM	0.0675 mL	0.3375 mL	0.6749 mL	1.6874 mL

Keywords

Cinnamic acid

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Cinnamic acid

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Food Additive Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Human Metabolite Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cinnamic acid

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Cinnamic acid Related Classifications

HY-N0610A Related Classifications